19/04/2015 11:46:05 Free Membership Login

Cyprotex News (LSE:CRX)

DateTimeSource
Headline
04/15/20154:42AMALNCCyprotex Predicts Profit Return After First Operating Loss For Seven Years
LONDON (Alliance News) - Cyprotex PLC Wednesday reported its first annual operating loss in seven years in 2014 as investments in an acquisition and bolstering its existing offerings proved more difficult than it had expected, but revenue grew strongly and it predicted that it would return to profit in 2015. The drug research... More...>>
04/15/20152:27AMALNC*Cyprotex Says Has Made Positive Start And Expects To Return To Profitability In 2015
More...>>
04/15/20152:26AMALNC*Cyprotex 2014 Pretax Loss GBP4.0M, Widened From GBP1.2M In 2013
More...>>
04/15/20152:21AMALNC*Cyprotex 2014 Revenue Up 18% To GBP11.6M From GBP9.8M In 2013
More...>>
04/14/20153:47AMALNCCyprotex Launches In-Vitro Service To Identify Cardiotoxic Drugs
LONDON (Alliance News) - Cyprotex PLC Tuesday said it has launched a new in-vitro service to identify potential cardiotoxic liabilities of pharmaceuticals, using 3D cell culture methods and confocal high-content imaging technology. Cyprotex, a specialist ADME-Tox contract research organisation, said the 3D microtissues... More...>>
04/14/20152:01AMRNSNONCyprotex PLC Launch of in vitro service using 3D microtissues
TIDMCRX RNS Number : 0498K Cyprotex PLC 14 April 2015 Cyprotex PLC ("Cyprotex" or "the Company") Cyprotex launches in vitro service using spontaneously beating cardiac 3D microtissues 14(th) April, 2015; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announced today the launch of a... More...>>
03/31/20155:03AMALNCCyprotex Launches New Screening Laboratory At US Facility
LONDON (Alliance News) - Contract research company Cyprotex PLC on Tuesday said it has launched a high throughput screening laboratory at its US facility in Watertown near Boston. The new laboratory replicates its existing UK facility and houses automated liquid-handling instruments and analytical instruments. "Expansion... More...>>
03/31/20152:02AMRNSNONCyprotex PLC Launch of new laboratory in its US facility
TIDMCRX RNS Number : 8711I Cyprotex PLC 31 March 2015 Cyprotex PLC ("Cyprotex" or "the Company") Cyprotex launches new high throughput laboratory in its US facility 31(st) March, 2015; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announced today the launch of a new high throughput... More...>>
03/19/20155:40AMALNCCyprotex Launches Non-Animal Eye Damage Test Service
LONDON (Alliance News) - Cyprotex PLC on Thursday said it has launched a Short Time Exposure in-vitro testing service, an assay test developed for identifying potentially serious eye damage from new chemicals rather than the current method of testing on rabbit eyes. "The addition of the new STE service enables Cyprotex... More...>>
03/19/20153:02AMRNSNONCyprotex PLC Launch of Short Time Exposure Service
TIDMCRX RNS Number : 7759H Cyprotex PLC 19 March 2015 19(th) March 2015 Cyprotex PLC ("Cyprotex" or "the Company") Cyprotex launch Short Time Exposure service for identifying potential serious eye damage for new chemicals Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announce the... More...>>
03/12/20153:01AMRNSNONCyprotex PLC Appointment of Leader of Drug Transporter Team
TIDMCRX RNS Number : 2117H Cyprotex PLC 12 March 2015 Cyprotex PLC ("Cyprotex" or "the Company") Cyprotex appoints Dr Rob Elsby as Leader of Drug Transporter Team. Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the appointment of Dr Rob Elsby as Leader of its Drug Transporter... More...>>
12/22/20147:49AMALNCDIRECTOR DEALINGS: Cyprotex Non-Executive Buys 25,000 Shares
LONDON (Alliance News) - Cyprotex PLC Monday said Non-Executive Director Ralph Harris bought 25,000 shares at a price of 42.5 pence per share Friday. Following this transaction, Harris holds 235,514 shares, which represents 1.05% of the total voting rights. Shares in the medical research and development company were up... More...>>
11/19/20148:41AMALNCDIRECTOR DEALINGS: Cyprotex Non-Executive Director Purchases Shares
LONDON (Alliance News) - Cyprotex PLC Wednesday said Non-Executive Director Ralph Harris purchased 10,000 shares at a price of 39.0 pence per share on Tuesday. Following the transaction, Harris holds 210,514 shares, representing 0.94% of the issued share capital in the company. Cyprotex shares were down 1.3% to 39.00 pence... More...>>
11/14/201411:18AMALNCDIRECTOR DEALINGS: Cyprotex Chief Executive And Wife Buy Shares
LONDON (Alliance News) - Cyprotex PLC said Friday that Chief Executive Anthony Baxter bought 11,000 shares in the company at 40 pence each. His wife Helen Baxter has also bought 5,200 shares at the same price. Following these transactions Baxter has an interest in 132,374 shares, or less than 1.0%. Shares in Cyprotex are... More...>>
11/14/20142:53AMALNCCyprotex Warns On Full Year Amid Development Delays, Weak Demand
LONDON (Alliance News) - Cyprotex PLC on Friday issued a profit warning for the full year as the group came under pressure from delays in its development work and weaker-than-anticipated demand. The contract research organisation said the delays highlighted in its half-year results had continued to exacerbate in the second... More...>>
10/14/20145:11AMALNCCyprotex Launches Improved Version Of SenCeeTox Technology
LONDON (Alliance News) - Cyprotex PLC said Tuesday that it has launched an improved version of its SenCeeTox technology, a model used to predict 'in vitro' skin sensation. Cyprotex acquired the technology with CeeTox Inc in January. It is an in vitro model that uses multiple endpoints to predict skin sensation. In the... More...>>
10/14/20142:00AMRNSNONCyprotex PLC Enhanced SenCeeTox® technology
TIDMCRX RNS Number : 1708U Cyprotex PLC 14 October 2014 14 October 2014 Cyprotex PLC Enhanced SenCeeTox(R) technology for prediction of in vitro skin sensitisation Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces significant advances in its SenCeeTox(R) model for the... More...>>
10/09/20144:30AMALNCCyprotex Now Able To Offer Full Range Of In Vitro Drug Transporter Assays
LONDON (Alliance News) - Cyprotex PLC Thursday said it has expanded its in-house drug transporter services, and can now offer a full range of in vitro drug transporter assays that are recommended by the regulatory authorities. The contract research organisation has recently bought two transport services, and got a permit... More...>>
10/09/20142:01AMRNSNONCyprotex PLC Expansion of Drug Transporter Capabilities
TIDMCRX RNS Number : 8182T Cyprotex PLC 09 October 2014 9 October 2014 Cyprotex PLC Expansion of Drug Transporter Capabilities Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of its in-house drug transporter services. Cyprotex can now offer the full range... More...>>
10/01/20144:22AMALNCCyprotex Buys New Instruments To Expand Toxicology Facility
LONDON (Alliance News) - Cyprotex PLC said Wednesday that it had expanded its toxicology facility to include high content 3D tissue analysis and advanced mitochondrial toxicity analysis after buying new instruments. Cyprotex bought new instruments including a Thermo Scientific ArrayScan XTI high-content screening platform... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse crx150419 11:46